Abstract
Despite considerable advances in chemotherapeutics, mortality rate of breast cancer is still on the rise. This is largely due to shortcomings associated with chemotherapeutics medicines. Firstly, majority of medicines lack specificity, second most of them get solubilized before reaching the target resulting in reduced bioavailability of drug at target site. Introduction of nanotechnology in medicine offers some promising solutions. Since nanoparticles have small size with at least one dimension less than 100 nm, they have unique interaction with biological systems at molecular level. Their large surface to volume ratio gives an excellent opportunity to manipulate them for desired properties, i.e., targeting cancer cells, loading drug and genetic materials, controlled release, increasing cellular uptake thereby increasing selectivity and bioavailability to target site. By targeting cancer cells, nanomedicine can help in reducing effects of systemic toxicity of chemotherapeutic drugs. Both metallic and non-metallic nanoparticles are currently studied as emerging therapeutic platforms against breast cancer therapy. Not only this, but nanoparticles can also be used as a platform to construct a delivery system where therapeutics and diagnostics can be integrated leading to the development of theranostic (Therapy + Diagnostic) nanoparticles. In this chapter, we have discussed in detail the potential of these nanoparticle-based treatment, its pharmacokinetics, their mechanism of controlled release, and their application as theranostic agents in breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abu Lila AS, Kiwada H, Ishida T (2013) The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release 172(1):38–47. https://doi.org/10.1016/j.jconrel.2013.07.026
Afzal M, Ameeduzzafar, Alharbi KS, Alruwaili NK, Al-Abassi FA, Al-Malki AAL, Kazmi I, Kumar V, Kamal MA, Nadeem MS, Aslam M, Anwar F (2021) Nanomedicine in treatment of breast cancer—a challenge to conventional therapy. Semin Cancer Biol 69:279–292. https://doi.org/10.1016/j.semcancer.2019.12.016
Ahmed Hamed Khalil I, Arida IA, Ahmed M (2020) Introductory chapter: overview on nanomedicine market. In: Current and future aspects of nanomedicine. IntechOpen, London. https://doi.org/10.5772/intechopen.91890
Aires A, Ocampo SM, Simões BM, Rodríguez MJ, Cadenas JF, Couleaud P, Spence K, Latorre A, Miranda R, Somoza Á, Clarke RB, Carrascosa JL, Cortajarena AL (2016) Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells. Nanotechnology 27(6):065103. https://doi.org/10.1088/0957-4484/27/6/065103
American Cancer Society (2019) Breast cancer early detection and diagnosis American Cancer Society recommendations for the early detection of breast cancer
Astley SM (2014) Computer-based detection and prompting of mammographic abnormalities. Br J Radiol 77(Spec. Iss. 2). https://doi.org/10.1259/BJR/30116822
Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF, Correspondence MF, Attia TF (2019) An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol 71(1185). https://doi.org/10.1111/jphp.13098
Bae KH, Lee K, Kim C, Park TG (2011) Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials 32(1):176–184. https://doi.org/10.1016/J.BIOMATERIALS.2010.09.039
Balalaeva IV, Zdobnova TA, Krutova IV, Brilkina AA, Lebedenko EN, Deyev SM (2012) Passive and active targeting of quantum dots for whole-body fluorescence imaging of breast cancer xenografts. J Biophotonics 5(11–12):860–867. https://doi.org/10.1002/JBIO.201200080
Bor G, Azmi IDM, Yaghmur A (2019) Nanomedicines for cancer therapy: current status, challenges and future prospects. Ther Deliv 10(2):113–132. https://doi.org/10.4155/tde-2018-0062
Bozzer S, Bo MD, Toffoli G, Macor P, Capolla S (2021) Nanoparticles-based oligonucleotides delivery in cancer: role of zebrafish as animal model. Pharmaceutics 13(8). https://doi.org/10.3390/pharmaceutics13081106
Bressler EM, Kim J, Shmueli RB, Mirando AC, Bazzazi H, Lee E, Popel AS, Pandey NB, Green JJ (2018) Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells. J Biomed Mater Res A 106:1753–1764. https://doi.org/10.1002/jbm.a.36360
Candiani G, Pezzoli D, Ciani L, Chiesa R, Ristori S (2010) Bioreducible liposomes for gene delivery: from the formulation to the mechanism of action. PLoS One 5(10):e13430. https://doi.org/10.1371/JOURNAL.PONE.0013430
Cao Z, Lee G, Wang YA, Sajja HK, Wang L, Long R, Barwick BG, Leyland-Jones B, Wood WC, Nie S, Mao H, Yang L (2010) Abstract 5482: Theranostic nanoparticles for targeted therapy of triple negative breast cancer and for monitoring therapeutic response by MRI. Cancer Res 70(8 Suppl):5482. https://doi.org/10.1158/1538-7445.AM10-5482
Chandrawati R, Odermatt PD, Chong S-F, Price AD, Städler B, Caruso F (2011) Triggered cargo release by encapsulated enzymatic catalysis in capsosomes. Nano Lett 11(11):4958–4963. https://doi.org/10.1021/NL202906J
Chattopadhyay N, Cai Z, Pignol JP, Keller B, Lechtman E, Bendayan R, Reilly RM (2010) Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer. Mol Pharm 7(6):2194–2206. https://doi.org/10.1021/mp100207t
Chen C, Peng J, Xia H, Wu Q, Zeng L, Xu H, Tang H, Zhang Z, Zhu X, Pang D, Li Y (2010) Quantum-dot-based immunofluorescent imaging of HER2 and ER provides new insightsinto breast cancer heterogeneity. Nanotechnology 21(9):095101. https://doi.org/10.1088/0957-4484/21/9/095101
Conceição DS, Ferreira DP, Ferreira LFV (2013) Photochemistry and cytotoxicity evaluation of heptamethinecyanine near infrared (NIR) dyes. Int J Mol Sci 14(9):18557–18571. https://doi.org/10.3390/IJMS140918557
Dams ETM, Laverman P, Oyen WJG, Storm G, Scherphof GL, Van Der Meer JWM, Corstens FHM, Boerman OC (2000) Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292(3):1071–1079
Durr NJ, Larson T, Smith DK, Korgel BA, Sokolov K, Ben-Yakar A (2007) Two-photon luminescence imaging of cancer cells using molecularly targeted gold nanorods. Nano Lett 7:941–945
El-Sahli S, Hua K, Sulaiman A, Chambers J, Li L, Farah E, Mcgarry S, Liu D, Zheng P, Lee S-H, Cui J, Ekker M, Côté M, Alain T, Li X, D’costa VM, Wang L, Gadde S (2021) A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature. Cell Death Dis 12:8. https://doi.org/10.1038/s41419-020-03308-w
Enteshari S, Varshosaz J, Minayian M, Hassanzadeh F (2018) Antitumor activity of raloxifene-targeted poly(styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice. Investig New Drugs 36(2):206–216. https://doi.org/10.1007/s10637-017-0533-1
Espinosa A, Silva AKA, Sánchez-Iglesias A, Grzelczak M, Péchoux C, Desboeufs K, Liz-Marzán LM, Wilhelm C (2016) Cancer cell internalization of gold nanostars impacts their photothermal efficiency in vitro and in vivo: toward a plasmonic thermal fingerprint in tumoral environment. Adv Healthc Mater 5(9):1040–1048. https://doi.org/10.1002/adhm.201501035
Faa G, Gerosa C, Fanni D, Lachowicz JI, Nurchi VM (2017) Gold-old drug with new potentials. Curr Med Chem 25(1). https://doi.org/10.2174/0929867324666170330091438
Fabbro C, Ali-Boucetta H, Da Ros T, Bianco A, Kostarelos K, Prato M (2012) Targeting carbon nanotubes against cancer. Chem Commun 48(33). https://doi.org/10.1039/c2cc17995d
Fasolo D, Bassani VL, Teixeira HF (2009) Development of topical nanoemulsions containing quercetin and 3-O-methylquercetin. Pharmazie 64(11):726–730. https://doi.org/10.1691/PH.2009.8357
Gao Y, Tang M, Leung E, Svirskis D, Shelling A, Wu Z (2020) Dual or multiple drug loaded nanoparticles to target breast cancer stem cells. RSC Adv 10(32). https://doi.org/10.1039/d0ra02801k
He H, Xie C, Ren J (2008) Nonbleaching fluorescence of gold nanoparticles and its applications in cancer cell imaging. Anal Chem 80(15):5951–5957. http://www.ncbi.nlm.nih.gov/pubmed/18590338
Ilinskaya AN, Dobrovolskaia MA (2016) Understanding the immunogenicity and antigenicity of nanomaterials: past, present and future. Toxicol Appl Pharmacol 299. https://doi.org/10.1016/j.taap.2016.01.005
Jafari A, Salouti M, Shayesteh SF, Heidari Z, Rajabi AB, Boustani K, Nahardani A (2015) Synthesis and characterization of Bombesin-superparamagnetic iron oxide nanoparticles as a targeted contrast agent for imaging of breast cancer using MRI. Nanotechnology 26(7):075101. https://doi.org/10.1088/0957-4484/26/7/075101
Jubin T, Kadam A, Jariwala M, Bhatt S, Sutariya S, Gani AR, Gautam S, Begum R (2016) The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival. Cell Prolif 49(4):421–437. https://doi.org/10.1111/cpr.12268
Kamaly N, Yameen B, Wu J, Farokhzad OC (2016) Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev 116(4):2602–2663. https://doi.org/10.1021/ACS.CHEMREV.5B00346
Kandasamy G, Maity D (2015) Recent advances in superparamagnetic iron oxide nanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics. Int J Pharm 496(2):191–218. https://doi.org/10.1016/j.ijpharm.2015.10.058
Keraliya RA, Patel C, Patel P, Keraliya V, Soni TG, Patel RC, Patel MM (2012) Osmotic drug delivery system as a part of modified release dosage form. ISRN Pharm 2012:1–9. https://doi.org/10.5402/2012/528079
Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W (1998) Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn Reson Med 40(2):236–242. https://doi.org/10.1002/MRM.1910400209
Kumar A, Mazinder Boruah B, Liang XJ (2011) Gold nanoparticles: promising nanomaterials for the diagnosis of cancer and HIV/AIDS. J Nanomater 2011. https://doi.org/10.1155/2011/202187
Kumar S, Diwan A, Singh P, Gulati S, Choudhary D, Mongia A, Shukla S, Gupta A (2019) Functionalized gold nanostructures: promising gene delivery vehicles in cancer treatment. RSC Adv 9(41):23894–23907. https://doi.org/10.1039/c9ra03608c
Lee Y, Thompson DH (2017) Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(5). https://doi.org/10.1002/WNAN.1450
Lee Ventola C (2012) The nanomedicine revolution: part 1: emerging concepts. P and T 37(9):512–518
Lee J, Chatterjee DK, Lee MH, Krishnan S (2014) Gold nanoparticles in breast cancer treatment: promise and potential pitfalls. Cancer Lett 347(1). https://doi.org/10.1016/j.canlet.2014.02.006
Liu E, Zhang M, Huang Y (2016) Pharmacokinetics and pharmacodynamics (PK/PD) of. In: Zhao Y, Shen Y (eds) Biomedical nanomaterials, 1st edn. Wiley, pp 1–60
Ma Q, Nakane Y, Mori Y, Hasegawa M, Yoshioka Y, Watanabe TM, Gonda K, Ohuchi N, Jin T (2012) Multilayered, core/shell nanoprobes based on magnetic ferric oxide particles and quantum dots for multimodality imaging of breast cancer tumors. Biomaterials 33(33):8486–8494. https://doi.org/10.1016/J.BIOMATERIALS.2012.07.051
MaHam A, Tang Z, Wu H, Wang J, Lin Y (2009) Protein-based nanomedicine platforms for drug delivery. Small 5(15). https://doi.org/10.1002/smll.200801602
Mamot C, Ritschard R, Wicki A, Küng W, Schuller J, Herrmann R, Rochlitz C (2012) Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. J Drug Target 20(5). https://doi.org/10.3109/1061186X.2012.680960
McCarley RL (2012) Redox-responsive delivery systems. Annu Rev Anal Chem 5:391–411. https://doi.org/10.1146/annurev-anchem-062011-143157
Menon JU, Jadeja P, Tambe P, Vu K, Yuan B, Nguyen KT (2013) Nanomaterials for photo-based diagnostic and therapeutic applications. Theranostics 3(3):152–166. https://doi.org/10.7150/thno.5327
Moreira R, Granja A, Pinheiro M, Reis S (2021) Nanomedicine interventions in clinical trials for the treatment of metastatic breast cancer. Appl Sci (Switzerland) 11(4). https://doi.org/10.3390/app11041624
Moss DM, Siccardi M (2014) Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. Br J Pharmacol 171(17):3963–3979. https://doi.org/10.1111/bph.12604
Núñez C, Estévez SV, del Pilar Chantada M (2018) Inorganic nanoparticles in diagnosis and treatment of breast cancer. J Biol Inorg Chem 23(3):331–345. https://doi.org/10.1007/S00775-018-1542-Z
Panagi M, Voutouri C, Mpekris F, Papageorgis P, Martin MR, Martin JD, Demetriou P, Pierides C, Polydorou C, Stylianou A, Louca M, Koumas L, Costeas P, Kataoka K, Cabral H, Stylianopoulos T (2020) Supporting information title: TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple-negative breast cancer microenvironment towards anti-tumor immunity. Therenostics 10(4):1910–1992
Park JW (2002) Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4(3):95–99. https://doi.org/10.1186/bcr432
Park J-H, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ (2008) Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem 120(38):7394–7398. https://doi.org/10.1002/ANGE.200801810
Pita R, Ehmann F, Papaluca M (2016) Nanomedicines in the EU—regulatory overview. AAPS J 18(6). https://doi.org/10.1208/s12248-016-9967-1
Poon W, Zhang YN, Ouyang B, Kingston BR, Wu JLY, Wilhelm S, Chan WCW (2019) Elimination pathways of nanoparticles [research-article]. ACS Nano 13(5):5785–5798. https://doi.org/10.1021/acsnano.9b01383
Sánchez A, Mejía SP, Orozco J (2020) Recent advances in polymeric nanoparticle-encapsulated drugs against intracellular infections. Molecules 25(16). https://doi.org/10.3390/MOLECULES25163760
Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33. https://doi.org/10.3322/caac.21654
Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, Chourasia MK (2017) Nanoemulsion: concepts, development and applications in drug delivery. J Control Release 252:28–49. https://doi.org/10.1016/J.JCONREL.2017.03.008
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):1–41. https://doi.org/10.3322/caac.21660
Tada H, Higuchi H, Wanatabe TM, Ohuchi N (2007) In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res 67(3):1138–1144. https://doi.org/10.1158/0008-5472.CAN-06-1185
Talluri S, Malla RR (2019) Superparamagnetic iron oxide nanoparticles (SPIONs) for diagnosis and treatment of breast, ovarian and cervical cancers. Curr Drug Metab 20(12). https://doi.org/10.2174/1389200220666191016124958
Tang Y, Soroush F, Tong Z, Kiani MF, Wang B (2017) Targeted multidrug delivery system to overcome chemoresistance in breast cancer. Int J Nanomedicine 12:671. https://doi.org/10.2147/IJN.S124770
Tayeb HH, Sainsbury F (2018) Nanoemulsions in drug delivery: formulation to medical application. Nanomedicine 13(19):2507–2525. https://doi.org/10.2217/NNM-2018-0088
Thorat ND, Bauer J (2020) Nanomedicine: next generation modality of breast cancer therapeutics. In: Nanomedicines for breast cancer theranostics. Elsevier Inc., Amsterdam. https://doi.org/10.1016/b978-0-12-820016-2.00001-x
Trimboli RM, Giorgi Rossi P, Battisti NML, Cozzi A, Magni V, Zanardo M, Sardanelli F (2020) Do we still need breast cancer screening in the era of targeted therapies and precision medicine? Insights Imaging 11(1). https://doi.org/10.1186/s13244-020-00905-3
Wang H, Liu Y, He R, Xu D, Zang J, Weeranoppanant N, Dong H, Li Y (2020a) Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery. Biomater Sci 8(2). https://doi.org/10.1039/c9bm01392j
Wang Y, Pi C, Feng X, Hou Y, Zhao L, Wei Y (2020b) The influence of nanoparticle properties on oral bioavailability of drugs. Int J Nanomedicine 15. https://doi.org/10.2147/IJN.S257269
Wu D, Si M, Xue H-Y, Wong H-L (2017) Nanomedicine applications in the treatment of breast cancer: current state of the art. Int J Nanomedicine 12:5879. https://doi.org/10.2147/IJN.S123437
Yan C, Wu Y, Feng J, Chen W, Liu X, Hao P, Yang R, Zhang J, Lin B, Xu Y, Liu R (2013) Anti-αvβ3 antibody guided three-step pretargeting approach using magnetoliposomes for molecular magnetic resonance imaging of breast cancer angiogenesis. Int J Nanomedicine 8:245. https://doi.org/10.2147/IJN.S38678
Yang Z, Sun N, Cheng R, Zhao C, Liu J, Tian Z (2017) Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. J Mater Chem B 5(33). https://doi.org/10.1039/c7tb01510k
Yezhelyev MV, Al-Hajj A, Morris C, Marcus AI, Liu T, Lewis M, Cohen C, Zrazhevskiy P, Simons JW, Rogatko A, Nie S, Gao X, O’Regan RM (2007) In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots. Adv Mater 19(20):3146–3151. https://doi.org/10.1002/ADMA.200701983
Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, Zentgraf H, Bock M, Eisenhut M, Semmler W, Kiessling F (2007) Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 67(4):1555–1562. https://doi.org/10.1158/0008-5472.CAN-06-1668
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Riaz, R., Ahmad, A. (2022). Nanoparticles: Emerging Diagnostic and Therapeutic Agents for Breast Cancer Treatment. In: Shakil Malik, S., Masood, N. (eds) Breast Cancer: From Bench to Personalized Medicine. Springer, Singapore. https://doi.org/10.1007/978-981-19-0197-3_19
Download citation
DOI: https://doi.org/10.1007/978-981-19-0197-3_19
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-0196-6
Online ISBN: 978-981-19-0197-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)